Convidecia is approved as a heterologous booster for COVID 19 in China.- CanSino Biologics
CanSino Biologics Inc. announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (“Ad5-nCoV”, trade name: Convidecia™) has been approved by the Joint Prevention and Control Mechanism of the State Council of China (“State Council”) as a heterologous booster, making it the first adenovirus-vectored vaccine to be included in the heterologous vaccination program in China.
According to the State Council, for those aged 18 and above who have completed a 6-month vaccination schedule using inactivated COVID-19 vaccines, and those who have not been administered a homologous booster, being administered CanSinoBIO’s Convidecia as a heterologous booster can significantly increase the neutralizing antibody levels with proven safety.
Heterologous booster vaccination refers to the use of vaccine boosters from different technology
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.